Nilotinib

證據等級: L5

預測適應症: 1 個

Nilotinib: From Chronic Myeloid Leukemia to Dermatofibrosarcoma Protuberans

One-Sentence Summary

Nilotinib is a BCR-ABL/PDGFR/KIT tyrosine kinase inhibitor originally developed for chronic myeloid leukemia (CML). The TxGNN model predicts it may be effective for dermatofibrosarcoma protuberans (DFSP), a rare PDGFRB-driven soft-tissue sarcoma, but this direction is currently supported by only 1 mechanism-focused publication and no registered clinical trials.

Note: The evidence pack did not return a regulatory-sourced original indication or MOA text for this drug (both flagged as data gaps — DG001/DG002); the indication above is well-established public drug information for nilotinib, not extracted from the evidence pack.

Quick Overview

Item	Content
Original Indication	Chronic Myeloid Leukemia (not present in evidence pack; publicly known indication)
Predicted New Indication	Dermatofibrosarcoma Protuberans
TxGNN Prediction Score	99.31%
Evidence Level	L4
Germany Market Status	✗ Not marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available for nilotinib in this evidence pack. Based on known information, nilotinib is a second-generation tyrosine kinase inhibitor that targets BCR-ABL, PDGFR, and KIT, and its efficacy in chronic myeloid leukemia is well established.

The supporting literature (Roskoski, 2018) reviews the mechanistic role of small-molecule PDGFR inhibitors in treating neoplastic disorders. Dermatofibrosarcoma protuberans is characteristically driven by a COL1A1-PDGFB gene fusion that causes constitutive activation of PDGFR-beta signaling. Because nilotinib inhibits PDGFR, there is a plausible mechanistic rationale for repurposing — this mirrors the rationale that has led to off-label use of the related TKI imatinib in DFSP.

However, this rationale is currently based on class-level mechanism literature rather than nilotinib- or DFSP-specific clinical data, which limits confidence in the prediction at this stage.

Clinical Trial Evidence

Currently no related clinical trials registered

Literature Evidence

PMID	Year	Type	Journal	Key Findings
29408302	2018	Review	Pharmacological Research	Reviews the role of small-molecule PDGFR inhibitors (a class that includes nilotinib) in treating neoplastic disorders driven by aberrant PDGF/PDGFR signaling

Germany Market Information

Nilotinib is currently not marketed in Germany according to the available regulatory data (0 authorizations on record), so no product/authorization table is available.

Cytotoxicity

Item	Content
Cytotoxicity Classification	Targeted therapy (BCR-ABL/PDGFR/KIT tyrosine kinase inhibitor)
Myelosuppression Risk	Please refer to the package insert warnings and precautions
Emetogenicity Classification	Please refer to the package insert warnings and precautions
Monitoring Items	Please refer to the package insert warnings and precautions
Handling Protection	Please refer to the package insert warnings and precautions

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction rests on a single class-level mechanism review with no DFSP- or nilotinib-specific clinical trials, and the evidence pack is missing critical MOA, label warning, contraindication, and Germany regulatory data — insufficient to move past initial screening.

To proceed, the following is needed:

TFDA/BfArM label warnings and contraindications (DG001, blocking)
DrugBank-sourced mechanism of action data (DG002)
DFSP-specific clinical evidence (case series, trials, or off-label use reports for TKIs in DFSP)
Confirmation of Germany market/authorization status for nilotinib
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.